Enterprise Value
745.2M
Cash
342.6M
Avg Qtr Burn
-17.9M
Short % of Float
11.33%
Insider Ownership
12.54%
Institutional Own.
84.35%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bitopertin (GlyT1 inhibitor) Details erythropoietic porphyrias, X-linked protoporphyria | Phase 2 Update | |
DISC-0974 Details Myelofibrosis, Anemia, Chronic kidney disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1/2 Data readout | |
Bitopertin (GlyT1 inhibitor) Details Anemia, Rare genetic disease | Phase 1/2 Update | |
DISC-3405 (formerly MWTX-003) Details Polycythemia vera, Cancer, Blood cancer | Phase 1 Update | |
GEM103 Details Age-related macular degeneration | Failed Discontinued | |
GEM103 Details Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued |